Matthew Liang

Professor Emeritus, Rheumatology, MD, MPH

 

Appointments

  • Professor of Medicine, Harvard School of Medicine
  • Professor, Department of Health Policy and Management, Harvard School of Public Health
  • Arthritis Research Canada Scientist Emeritus 

Research Interests

  • Valuation of the surgical, medical, and rehabilitation interventions in arthritis and musculoskeletal diseases
  • Epidemiology of rheumatic disability
  • Modifiable risk factors in high risk populations with systemic lupus erythematosus, rheumatoid arthritis, osteoarthritis
  • Development of patient-centered outcome measures for clinical trials
  • Epidemiology of connective tissue diseases and etiologic risk factors
  • Clinical decision making
  • Doctor-patient communication
  • Chronic disease health policy

Dr. Liang is an internationally renowned clinician/scientist who lent his considerable expertise to the development of Arthritis Research Canada. As a visiting professor, he leads a coalition to develop, provide and secure coordinated and comprehensive patient-centred services for people with arthritis and musculoskeletal diseases in British Columbia.

Learn more

A graduate of Harvard Medical School and Harvard School of Public Health, Dr. Liang has made major contributions to the field of rheumatology, especially with regard to health outcomes research. He is a gifted communicator who has served as a guest lecturer and visiting professor at major universities throughout North America and Europe. He also organizes and conducts clinical and health policy research with Arthritis Research Canada partners and others around the world.

Dr. Liang’s areas of research interest include the valuation of the surgical, medical, and rehabilitation interventions in arthritis and musculoskeletal diseases; the epidemiology of rheumatic disability; modifiable risk factors in high risk populations with systemic lupus erythematosus, rheumatoid arthritis, osteoarthritis; the development of patient-centered outcome measures for clinical trials; the epidemiology of connective tissue diseases and etiologic risk factors; clinical decision making; doctor-patient communication; and chronic disease health policy.